Aprea Current Deferred Revenue from 2010 to 2026
| APRE Stock | USD 0.66 0.03 4.35% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 476.1 K | Current Value 423.2 K | Quarterly Volatility 28 K |
Check Aprea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aprea Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 541.8 K, Selling General Administrative of 8.1 M or Total Revenue of 1.8 M, as well as many indicators such as Price To Sales Ratio of 22.67, Dividend Yield of 0.0 or PTB Ratio of 0.89. Aprea financial statements analysis is a perfect complement when working with Aprea Therapeutics Valuation or Volatility modules.
Aprea | Current Deferred Revenue | Build AI portfolio with Aprea Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:Check out the analysis of Aprea Therapeutics Correlation against competitors. For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Aprea diversify its offerings? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aprea Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Understanding Aprea Therapeutics requires distinguishing between market price and book value, where the latter reflects Aprea's accounting equity. The concept of intrinsic value - what Aprea Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aprea Therapeutics' price substantially above or below its fundamental value.
Understanding that Aprea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aprea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aprea Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.